ReviewClinical immunology (Orlando, Fla.)2011
Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges.
Review in Clinical immunology (Orlando, Fla.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias.The Journal of experimental medicine · 2014Trial
- Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.Clinical and experimental immunology · 2014Trial
- Trial
- Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms.Current obesity reports · 2025Review
- Role of Immune Cells and Immunotherapy in Multiple Myeloma.Life (Basel, Switzerland) · 2024Review
- Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT).Oncogene · 2024Article
- Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment.Molecular therapy oncolytics · 2023Article
- Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.Frontiers in oncology · 2023Article
- Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.Pathology oncology research : POR · 2023Review
- Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.Frontiers in oncology · 2022Review
- Current Progress in CAR-T Cell Therapy for Hematological Malignancies.Journal of Cancer · 2021Review
- The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.Cells · 2020Review
- Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.Nature cancer · 2020Article
- Immunotherapy of multiple myeloma.The Journal of clinical investigation · 2020Review
- Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.Cell stem cell · 2019Article
- Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease.Journal of cellular and molecular medicine · 2018Article
- Checkpoint Inhibition in Myeloma: Opportunities and Challenges.Frontiers in immunology · 2018Review
- Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression.Frontiers in immunology · 2018Review
- Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.Frontiers in immunology · 2018Review
- Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma.Leukemia · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow. Tumor cells in myeloma express CD1d and are sensitive to lysis by CD1d restricted natural killer T (NKT) cells. Here we discuss recent studies to harness the properties of these cells in the context of human myeloma. In spite of large body of preclinical data, attempts to fully harness the properties of these cells in the clinic are in early stages. Early phase clinical studies document the capacity of human monocyte-derived dendritic cells to expand NKT cells in vivo in myeloma patients. These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.